Arsenal Acquires Automation Solutions Provider Eckhart from LFM Capital

Arsenal Capital Partners (“Arsenal”), a private equity firm that specializes in investments in industrial growth and healthcare companies, today announced that it has acquired Eckhart Holdings, Inc. (“Eckhart”), a leading automation solutions provider from LFM Capital. Terms of the transaction were not disclosed.

Eckhart’s advanced engineering, design, simulation, and integration services, along with proprietary tooling and other automation and robotics systems, support customers at critical points in the automation value chain. Eckhart partners with blue-chip customers to design and implement automation solutions that solve complex problems and improve accuracy and efficiency in a number of attractive end markets, including ecommerce, engineered products, electric vehicles, transportation, and consumer products.

Andy Storm, CEO of Eckhart, commented, “We are excited to announce this strategic growth investment from Arsenal, which will enable us to take our business to new heights, scale our team, and better serve our customers. Arsenal’s extensive knowledge of the sector and track record of building high-growth, innovation-rich industrial technology businesses gave us confidence that they are the right partner.”

Aaron Wolfe, an Investment Partner of Arsenal, said, “We are thrilled to work closely with Eckhart’s senior leadership team to support a world-class automation platform in its next phase of growth. Eckhart’s solutions are critical to driving higher productivity, efficiency and precision, which is increasingly more valuable as customers compete on a global scale. Arsenal plans to invest a significant amount of incremental capital to accelerate growth, augment the solution set, and further penetrate attractive end markets.”

Daniel Burseth, Vice President of Eckhart, remarked, “The partnership with Arsenal comes at an opportune time as our customers invest at a record rate in automation for their operations. With Arsenal’s industrial track record and continued investment in expanding capabilities, Eckhart will become an even more important partner to a global customer base.”

Sal Gagliardo, an Operating Partner of Arsenal, added, “As systems increase in complexity, the design and integration of automation solutions becomes essential to efficient operations. We see significant opportunity ahead to leverage our collective industry expertise and deep financial resources to make Eckhart a clear innovation leader. As a firm, Arsenal will continue to invest in automation megatrends.

William Blair & Company L.L.C. served as financial advisor to Eckhart and LFM Capital on this transaction, and Bass, Berry & Sims PLC served as legal advisor to Eckhart and LFM. Harris Williams LLC served as financial advisor to Arsenal, and Kirkland & Ellis LLP served as legal advisor to Arsenal.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”